InvestorsHub Logo
Followers 38
Posts 2912
Boards Moderated 0
Alias Born 06/05/2012

Re: Darwinian post# 1139

Friday, 07/25/2014 2:57:52 PM

Friday, July 25, 2014 2:57:52 PM

Post# of 3833
I'm sure they now regret spending that $3500. But let's face it, AF already had GALT in his sights. His tweets (shown below) make that very clear. I assume that his comment referencing the "total omission of real clinical endpoints" is once again alluding to the lack of a biopsy to "verify" the reversal of fibrosis. I thought some of our posters here were very convincing that the tests being used are dependable and appropriate substitutes. And since Cohort 1 they have added the Fibroscan diagnostic as well. Given the somewhat significant health risks associated with taking a liver biopsy, it seemed to me that using the alternatives was a very reasonable approach.

When AF wants to attack a company, he will not let the truth stand in his way. JMHO

AF tweets...

"$GALT floods field with arcane/useless data to hide total omission of real clinical endpoints for NASH & fibrosis."

"After spending time with $ICPT NASH study this week for Mailbag, $GALT NASH trial is farce by comparison."

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News